We were delighted to welcome Poolbeg (POLB), the specialist clinical stage infectious disease biopharma company to the London South East webinar on Tuesday 28 February 2023. Poolbeg operates a capital light clinical model and is targeting the growing infectious disease market.
On the evening we were joined by both CEO Jeremy Skillington and Business Development VP David English. The company were keen to introduce you to David, who is responsible for out-licencing the severe influenza asset.
POLB's flagship product aimed at severe influenza is POLB 001 and the company published strong results from the first clinical trial early in January. Jeremy said he believed it has the potential to become a leading severe influenza treatment, and was very clear that he expects it to be able to address many different diseases across oncology and other fields such as avian flu, not just severe influenza. This is because POLB 001 is a master regulator and can control hyperinflammatory reactions caused by many diseases.
As ever Jeremy and David covered a lot of ground and it is worthwhile spending time looking at the considerable detail in the presentation again. For instance Oral GLP1 was mentioned in the Q&A.
On the evening we were joined by both CEO Jeremy Skillington and Business Development VP David English. The company were keen to introduce you to David, who is responsible for out-licencing the severe influenza.
Poolbeg Pharma (POLB)